Drug Trial Radar · NCT03691909
Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Sep 25, 2018
Primary completion
Aug 17, 2020
Study completion Sep 28, 2020
Sponsor
- Lead sponsor
- Hope Biosciences LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hope Biosciences is conducting a research study of an investigational product called Hope Biosciences autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Rheumatoid Arthritis (RA). The study purpose is to evaluate the safety profile of a single IV infusion of HB-adMSCs in subjects with clinical diagnosis of RA.
Conditions
- Rheumatoid Arthritis
Interventions
HB-adMSCsBiological
Hope Biosciences autologous adipose-derived mesenchymal stem cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Adverse Events and Serious Adverse EventsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Accurate Clinical Research
Pasadena, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.